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Discussion
We found that there was impaired water handling in most subjects given therapeutic doses of carbamazepine. This is therefore a physiological effect of the drug and not dependent on idiosyncrasy or additional drug treatment. The drug's effect on water metabolism may be shown only by stressing the subjects with a water load and in standard conditions is not enough to alter the plasma electrolyte concentrations. Only a minority of patients would be expected to develop overt water intoxication.
Our results do not suggest that the mode of action is by stimulating the secretion of antidiuretic hormone. The basal plasma AVP concentrations fell while subjects took the drug, which agrees with the results of other studies.5 6 We found no change in the plasma osmolality or electrolyte concentrations, which suggests that there is a fundamental resetting of osmoreceptors so that during periods of dehydration less antidiuretic hormone is secreted for a given plasma osmolality.
While diuresis is impaired during carbamazepine treatment, the plasma AVP concentration at peak diuresis is not altered when compared with that during a control water load test. This may be taken as further evidence against direct stimulation of the secretion of antidiuretic hormone. It suggests, however, that there is increased renal sensitivity to "normal" plasma concentrations of AVP. If the feedback mechanism via the osmoreceptors is intact then antidiuretic hormone secretion will be further reduced, which will compensate for the increased renal sensitivity. Therefore, if increased renal sensitivity to antidiuretic hormone is postulated there must also be a resetting of osmoreceptor regulation. This implies that when there is a large water load the osmoreceptors direct the hypothalamus to secrete an inappropriately high level of antidiuretic hormone. This argument assumes that the plasma AVP concentration at peak diuresis is not lower during carbamazepine medication simply because AVP secretion cannot be switched off any more.
There have been two reports of patients with symptomatic water intoxication due to carbamazepine, whose plasma AVP concentrations were inappropriately high yet returned to normal when the drug dosage was reduced.7 This would agree with disturbed autoregulation such as we postulate.
Our results suggest that the antidiuretic action of carbamazepine is due to a combination of resetting of osmoreceptors and increased renal sensitivity to antidiuretic hormone. The response of the osmoreceptors is blunted, so that during dehydration too little antidiuretic hormone is secreted and during overhydration too much is secreted. Under the influence of carbamazepine the osmoreceptors become lazy. Factor VIII dosage-All directors calculated their recommended doses to the nearest phial or pack so that blood product was never wasted. Of the 46 directors replying to the question, 33 based their recommendations on clinical response, 11 on both clinical response and assayed in-vivo factor VIII response, and two on assayed factor VIII response only. The average phial of concentrate contains 250 factor VIII units (range 210-310 units). The 33 directors who based their dosage on clinical response recommended that one or two phials be given on demand-that is, when the patient recognised that a bleed had started. Seven prescribed one phial as routine, eight two phials, and 13 one phial as routine with two phials for major joint bleeds. Five directors recommended one phial as routine for children and two for adults; apart from this distinction only five other directors mentioned body weight as a factor to be taken into account when calculating dosage for home treatment. Most directors issued onlv enough blood product for one to two months' treatment at a time. Both the practice of measuring in-vivo factor VIII activity response Follow up-The directors were asked to specify their procedures for following up haemophiliacs on home treatment. Forty replied to this section of the 1976 questionnaire and on the basis of their replies they were divided into four groups. Six centres performed regular follovw-up at least once a year, including full physical examination with musculoskeletal survey, radiology, and blood profile (at least a blood count, estimation of factor VIII activity, antibody screen, liver function tests, and screening test for hepatitis B antigen and antibody). They had access to specialists in orthopaedics, physical and social medicine and dentistry. Fourteen centres performed regular follow-up at least once a year which included at least a physical examination and measurement of joint ranges and blood count; one of these centres was for children only and saw adults only on an ad hoc basis. Sixteen centres merely checked the home transfusion records when patients presented for further supplies of blood product, and performed a blood count. The last group, of four centres, only checked the home treatment records. In all centres a blood count included estimation of haemoglobin and other red cell indices, white cell and platelet counts, and examination of a blood film.
The two surveys reported show the recent rise in the use of home treatment for patients with haemophilia A in the United Kingdom. In 1974 1589 severely affected (factor VIII <20,) haemophiliacs of all ages were known to the haemophilia centre directors.5 It may be assumed that about 250°, of these patients were unsuitable for home treatment because of age, infrequency of haemorrhage, presence of factor VIII antibody, or inability to fulfil other criteria.4 The number of haemophiliacs (729) either on home treatment or reported as being suitable for it at the end of 1976 therefore represents about 600o of the potential total.
The 1976 figures for those patients either on home treatment or in training indicated an annual factor VIII requirement of 9-76 million units (488 x 20 000), with a potential annual requirement of 23 n& million units exclusively for home treatment. This is more than half the estimated total national requirement of 40 million units of factor VIII reported by Biggs,5 the remaining blood product being required to treat patients not on home treatment and to cover surgery and the management of complications, including the development of factor VIII antibodies.
Apart from the numbers of patients concerned, there are four variables that govern the demand for factor VIII for home treatment-the assessment of effective dosage, the use of prophylaxis, the adequacy of supply, and the risk of long-term side effects. Our results show that in the UK severely affected haemophiliacs are trained to treat themselves with comparatively low doses of factor VIII, the mean of 20 000 units per patient per year being about half that reported from some other countries.' This difference in dosage is very important in relation to the cost of home treatment, and there is an urgent need for comparative trials to determine whether it is of long-term clinical significance.
Although the rise in the use of prophylaxis reported in 1975 and 1976 is expected to be sustained in 1977 it is too early to calculate accurately the long-term effect of this type of treatment on blood product demand. In most cases reported prophylaxis was prescribed temporarily for a specific reason, usually to halt recurrent haemorrhage into a joint already damaged by haemophilic arthropathy, a return to on-demand treatment being indicated once the joint is quiescent with good function. Use of this limited prophylaxis was responsible for the 10°0 rise in factor VIII consumption in the Newcastle centre in 1976. Estimates of increased factor VIII demand for prophylaxis vary widely,6-'0 and, as with on-demand treatment, much of this variation seems to depend on the therapeutic aim, total suppression of haemorrhage demanding very high factor VIII consumption.
Home treatment for many of the haemophiliacs in the United Kingdom would have been impossible without recourse to factor VIII concentrates prepared by pharmaceutical companies. About 5500 of the blood product used for home treatment in 1976 was imported, importation being necessary because of continued shortfall in the production of NHS concentrate from the voluntary donor system of the Blood Transfusion Service. The cost of producing NHS concentrate has not been disclosed, but at a minimum commercial price of 8p per unit the potential cost of home treatment in the United Kingdom will be about £2m a year. In 1976 the Department of Health announced that the UK requirement for factor VIII concentrate would be met from NHS sources by mid-1977 after the grant of an additional ,CO5m to the Blood Transfusion Service."' This target has clearly not been met, nor could it have been in the absence of the necessary financial aid to increase fractionation capacity. It seems poor economic policy to invest only CO5m in a service which produces a very satisfactory factor VIII product and which could be self-sufficient, while continuing to pay Ilm to £2m a year on blood from paid donors in other countries. The difficulty of implementing home treatment in some areas is reflected in the continued use of cryoprecipitate, which, despite its disadvantages, remained the only product available for 15%' of haemophiliacs in 1976.
Both the need to carefully monitor the use of blood products and the need for continual surveillance of patients because of the possible long-term side effects of intensive transfusion demand adequate follow-up procedures. Perhaps the most disturbing aspect of the 1976 inquiry was the lack of adequate follow-up in some centres. The contemporary management of haemophilia is time-consuming and if it is to be effective it demands the integrated (usually part-time) services of many medical and paramedical workers. Many haemophilia centres still lack the staff and facilities required, despite the obligation on the Health Authorities to provide these, as set out in the Department of Health and Social Security Health circular HC(76)4. Introduction Soluble immune complexes have been reported in the sera of women in normal pregnancy,' and these may arise from a physiological immunological reaction between mother and child. Immune complexes can, however, cause a wide range of diseases, depending on, for example, the amount and type of complex. Many of the features of pre-eclampsia might be explained by excess or qualitatively abnormal circulating soluble immune complexes.2 We have therefore measured IgG-containing and Clq-binding complexes in the sera of women with severe pre-eclampsia and closely matched women with normal pregnancies.
Patients and methods
Sixteen pregnant women with severe pre-eclampsia were studied at gestational ages ranging from 28 to 40 weeks. The criteria for diagnosis were: (a) an increase of 30 mm Hg or more in the systolic blood Sixteen women with normal pregnancies (controls) were selected who matched the patients for gestational age and parity (except for one para 3 control who was matched with a para 4 patient).
Venous blood samples were allowed to clot at room temperature, separated within three hours, and stored in aliquots in liquid nitrogen until analysis. IgG immune complexes were measured by their inhibition of IgG latex agglutination by rabbit IgM anti-human IgG3; agglutination was measured by counting unagglutinated particles on an electronic counter. Clq-binding complexes were similarly measured using purified human Clq as the agglutinating reagent.3 Samples were analysed blind in duplicate and results were expressed as percentage inhibition of agglutination. In non-pregnant people levels of inhibition are considered significant only if they are 20 % or more.3
Results
All 16 patients with pre-eclampsia had detectable levels of IgG complexes, and inhibition of agglutination was greater than 20'% in 11 cases. Five controls had no detectable IgG complexes and only four had more than 200% inhibition (see table) . Similarly, 13 preeclamptic patients had raised levels of Clq-binding complexes compared with four controls. For both types of complexes mean titres were considerably higher in the patients than in the controls (P < 0-005; Wilcoxon's rank sum test). In the group as a whole the values of patients and controls overlapped, but most of the preeclamptic patients had higher values than their matched controls at each gestation studied.
Two patients who had very low levels of IgG complexes at 32 and 29 weeks' gestation (cases 2 and 3) had much higher levels of Clqbinding complexes (17.7 % and 33-2 % inhibition respectively).
Discussion
The cause of pre-eclampsia is unknown. It occurs predominantly in first pregnancies, and even a first trimester miscarriage is protective.4 This suggests that immunisation to fetal antigens may stimulate the maturation of maternal immune reactions that are necessary to prevent fetal allograft rejection. Pre-eclampsia may be caused by partial failure of these protective mechanisms.
Higher levels of circulating soluble immune complexes may not only be a marker of this relative failure but may also cause
